Stockscreener 앱 받기
34.53
2.27%
0.765
시간 외 거래:
34.59
0.06
+0.17%
Alkermes Plc 주식(ALKS)의 최신 뉴스
Alkermes (ALKS) nears 52-week high on increasing orexin receptor market interest - MSN
(ALKS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Avadel Stock Rises After Acquisition Offer By Alkermes - MSN
Alkermes plc stock (IE00B56GVS15): Is its neuroscience focus strong enough to drive steady upside? - AD HOC NEWS
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting - BioSpace
Wolfe Research initiates coverage of Alkermes (ALKS) with outperform recommendation - MSN
Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities - CSRwire
Alkermes (ALKS) Unveils Promising Data on Alixorexton for Narcol - GuruFocus
Alkermes to present narcolepsy drug data at neurology meeting - Investing.com
Alkermes to present narcolepsy drug data at neurology meeting By Investing.com - Investing.com Canada
Narcolepsy patients showed 13 weeks of gains in Alkermes study - Stock Titan
Robeco Institutional Asset Management B.V. Purchases 151,283 Shares of Alkermes plc $ALKS - MarketBeat
ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Alkermes (ALKS) Reveals Positive Findings on Lybalvi for Schizop - GuruFocus
Alkermes publishes 56-week study on Lybalvi negative symptoms By Investing.com - Investing.com Australia
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry - BioSpace
Alkermes publishes 56-week study on Lybalvi negative symptoms - Investing.com
Schizophrenia study tracks symptom gains for 56 weeks on LYBALVI - Stock Titan
Should Alkermes’ (ALKS) New Phase 3 Narcolepsy Program Reshape Its Sleep-Disorder Investment Narrative? - simplywall.st
Alkermes (ALKS) director Nancy Lurker exercises RSUs, netting 13,555 shares - Stock Titan
Tudor Investment Corp ET AL Takes Position in Alkermes plc $ALKS - MarketBeat
ALKS (Alkermes) Cash Receipts from Operating Activities - GuruFocus
Alkermes PLC (ALKS) Stock Down 4.5% but Still Overvalued -- GF S - GuruFocus
Alkermes PLC (ALKS) Stock Down 4.5% but Still Overvalued -- GF Score: 79/100 - GuruFocus
Will Alkermes plc benefit from government policyEarnings Growth Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
B of A Securities Raises Price Target for ALKS to $36 | ALKS Sto - GuruFocus
Market Fear: Is Alkermes plc stock showing strong momentum2026 PostEarnings & Capital Efficient Trading Techniques - baoquankhu1.vn
How (ALKS) Movements Inform Risk Allocation Models - Stock Traders Daily
Alkermes PLC (ALKS) Stock Price Down 4.08% on Apr 7 - GuruFocus
RBC Capital Adjusts Price Target on Alkermes Public to $44 From $45, Maintains Outperform Rating - marketscreener.com
Insider Sell Alert: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
Alkermes (NASDAQ:ALKS) EVP Sells $70,315.38 in Stock - MarketBeat
Alkermes (ALKS) EVP David Gaffin sells 2,034 shares in 10b5-1 trade - Stock Titan
Alkermes (NASDAQ: ALKS) 2026 proxy outlines CEO change, $1.48B 2025 revenue and Avadel acquisition - Stock Titan
Alkermes plc (NASDAQ: ALKS) Form 144 lists affiliate sale amounts - Stock Titan
Is Alkermes (ALKS) Building a Durable Sleep-Disorder Franchise With Its Brilliance Phase 3 Bet? - simplywall.st
Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program - CSRwire
Alkermes Starts Phase 3 Program for Narcolepsy Drug Candidate Alixorexton - Sleep Review
Alkermes plc (ALKS) stock price, news, quote and history - Yahoo Finance UK
Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
Alkermes stock hits 52-week high at $36.46 By Investing.com - Investing.com South Africa
Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN
1.84%
6.22%
자본화:
|
볼륨(24시간):